Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990881 | 1.00 | LMNA (0.50) | LMNAGLAMAPK1GRM5ALDH1A1 | |
| SCHEMBL990865 | 0.87 | NPC1 (0.46) | LMNAGRM5NPC1RAB9AL3MBTL1 | |
| SCHEMBL990087 | 0.86 | LMNA (0.50) | LMNAGRM5NPC1RAB9AL3MBTL1 | |
| SCHEMBL3377773 | 0.85 | GRM5 (0.46) | GRM5 | |
| SCHEMBL3377253 | 0.85 | GRM5 (0.46) | GRM5 | |
| SCHEMBL990107 | 0.84 | ALDH1A1 (0.49) | LMNAMAPK1GRM5ALDH1A1NPC1 | |
| SCHEMBL990808 | 0.84 | ALDH1A1 (0.49) | LMNAMAPK1GRM5ALDH1A1NPC1 | |
| SCHEMBL990869 | 0.83 | GRM5 (0.48) | GRM5NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL990822 | 0.83 | NPC1 (0.48) | LMNAMAPK1GRM5ALDH1A1NPC1 | |
| SCHEMBL1907158 | 0.83 | GRM5 (0.46) | LMNAGRM5ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011137206-A1 | PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS) | NOVARTIS AG (CH) | 2011-11-03 | — | — | WO | disclosed |
| EP-2320892-A2 | COMBINATION PRODUCTS | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |